

JC06 Rec'd PCT/PTO 22 AUG 2005

PCT  
#2

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on August 19, 2005

David Saliwanchik

David R. Saliwanchik, Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Patent Application

Docket No. GJE-7230

Serial No. 10/531,333

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : *not yet assigned*  
Art Unit : *not yet assigned*  
Applicants : John Gary Montana, Ian Fleming, Reinhold Tacke, Jurgen Daiss  
Serial No. : 10/531,333 ✓  
Filed : April 14, 2005  
Conf. No. : *not yet assigned*  
For : Heterocyclic Silicon Compounds and Their Use in the Treatment of Diseases  
or Conditions Associated with GNRH (Gonadotropin-Releasing Hormone)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


The above-referenced patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. Copies of the International Search Report and copies of the references cited therein were made available in the national stage file; however, for the Examiner's convenience, the applicants are enclosing herewith copies of the cited references as well as a copy of the International Search Report.

Attached is a PTO/SB/08 form which lists the references attached.

In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/gyl

Attachment: Form PTO/SB/08; copies of cited references  
Copy of International Search Report.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/531,333
				Filing Date	April 14, 2005
				First Named Inventor	John Gary Montana
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	1	of	2	Attorney Docket Number	GJE-7230

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 03/106446	12-24-2003	Pfizer Inc.	All	
	F2	WO 03/068769	08-21-2003	Pfizer Inc.	All	
	F3	WO 00/20358	04-13-2000	Agouron Pharmaceuticals, Inc.	All	
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/531,333
Filing Date	April 14, 2005
First Named Inventor	John Gary Montana
Group Art Unit	
Examiner Name	
Attorney Docket Number	GJE-7230

Sheet	2	of	2
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ANDERES, K. L. <i>et al.</i> "Biological Characterization of a Novel, Orally Active Small Molecule Gonadotropin-Releasing Hormone (GnRH) Antagonist Using Castrated and Intact Rats" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , May 2003, pp. 688-695, Vol. 305, No. 2.	
	R2	IATSIMIRSKAIA, E. A. <i>et al.</i> "Effect of Testosterone Suppression on the Pharmacokinetics of a Potent GnRH Receptor Antagonist" <i>Pharmaceutical Research</i> , February 2002, pp. 202-208, Vol. 19, No. 2.	
	R3	LUTHIN, D. R. <i>et al.</i> "Characterization of Mono- and Diaminopyrimidine Derivatives as Novel, Nonpeptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , December 16, 2002, pp. 3635-3639, Vol. 12, No. 24.	
	R4	LUTHIN, D. R. <i>et al.</i> "The Discovery of Novel Small Molecule Non-Peptide Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , December 2, 2002, pp. 3467-3470, Vol. 12, No. 23.	
	R5	TACKE, R. <i>et al.</i> "Sila-Substitution- A Useful Strategy for Drug Design" <i>Endeavour</i> , 1986, pp. 191-197, Vol. 10, No. 4.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.